(LEGN) – Press Releases
-
NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
-
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
-
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"
-
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
-
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
-
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
-
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
-
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
-
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
-
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
-
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of T
-
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
-
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
-
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector
-
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
-
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
-
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations
-
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CA
-
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
-
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
-
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
-
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
-
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
-
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
-
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
-
Riding the Waves of Foreign Trade: The Rise of China's Brands in 2023
-
ICHNOS SCIENCES WELCOMES LIDA PACAUD, M.D., AS NEW CHIEF MEDICAL OFFICER
-
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
-
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
-
Legend Biotech Announces Participation in Upcoming Investor Conferences
-
CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held
-
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
-
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
-
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
-
Legend Biotech Announces Participation in Upcoming Investor Conference
-
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
-
Exelixis Advances Board Refreshment Plan
-
Legend Biotech Announces Appointment of Chief Medical Officer
-
Legend Biotech Establishes Strategic Advisory Board
-
Genscript Biotech Reports 2022 Annual Results*
-
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
-
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
-
Legend Biotech Announces Participation in Upcoming Investor Conferences
-
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
-
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
-
Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC
Back to LEGN Stock Lookup
